~~<i id='8E019565C4'><strike id='8E019565C4'><tt id='8E019565C4'><pre id='8E019565C4'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

leisure time

hotspot

author：Wikipedia 2025-09-05 11:32:00 - browse：697

The Food and Drug Administration on Thursday approved a gene therapy to treat people with hemophilia A, an inherited and rare bleeding disorder.

The treatment, called Roctavian, is made by BioMarin Pharmaceutical. It was first approved in Europe in August 2022.

Roctavian is a one-time therapy that, in clinical trials, dramatically reduced bleeding episodes and helped patients live without the blood transfusions used to treat the disease. The FDA first rejected Roctavian in 2020, asking BioMarin to amass more data on its safety and long-term durability, and then delayed its decision again to account for additional evidence.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： Sanofi CEO defends move to abandon profit guidance, boost research

focus

Wikipedia

leisure time

explore

hotspot

AdobeAfteradrugentersthemarket,it’suptoFoodandDrugAdministrationregulatorstoensureitscontinuedsafety

WSS

Covid misinformation case heads to Supreme Court

Apple Vision Pro: A first look at health apps on the new VR headset

A clever new way to fix Medicaid and graduate medical education

FDA approves Recor Medical high blood pressure device

Medicare drug price negotiation’s day in court

AstraZeneca CEO says participant had neurological symptoms, could be discharged today

leisure time

hotspot

focus

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Study: New antibiotic targets gonorrhea as well as last existing drug

Bright Health sells Medicare Advantage business to Molina

UCSF medical school apologizes for unethical prisoner experiments

BioMarin wins approval for gene therapy to treat hemophilia A

ARCH Venture Partners is raising $3 billion for a life sciences fund

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Study: New antibiotic targets gonorrhea as well as last existing drug

Drug repurposing or repositioning? The language matters

More doctors should go into startup world

Wikipedia

Victims of gun violence feel impacts long after bullet wound

Even great ERs can’t make up for American health disparities

Ambulance rides for just $100? Advisers want major billing fixes

Excited delirium, Elijah McClain, and emergency physicians

Study: New antibiotic targets gonorrhea as well as last existing drug

Diversify hospital leadership teams to protect BIPOC patient health

leisure time

leisure time

explore

hotspot